Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines

Pain Med. 2005 Jul-Aug;6(4):305-14. doi: 10.1111/j.1526-4637.2005.00045.x.

Abstract

Objective: To review the evidence for dosing and efficacy of oral transmucosal fentanyl citrate in the management of pain and produce dosing guidelines.

Design: The scientific literature pertaining to oral transmucosal fentanyl citrate was reviewed, focusing upon its pharmacology and clinical experience with use in cancer and noncancer pain. Emphasis was upon published, peer-reviewed English language articles.

Results: Information was crucially examined and synthesized into guidelines for use and dosing of oral transmucosal fentanyl citrate in cancer and noncancer pain.

Conclusions: Oral transmucosal fentanyl citrate is a potent opioid delivery system, which, when used appropriately, is an effective treatment option for pain. Adherence to guidelines should promote its safe and efficacious use in a variety of clinical pain management settings.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / pharmacokinetics
  • Clinical Trials as Topic
  • Evidence-Based Medicine
  • Fentanyl / administration & dosage*
  • Fentanyl / pharmacokinetics
  • Guidelines as Topic
  • Humans
  • Male
  • Pain / drug therapy*

Substances

  • Analgesics, Opioid
  • Fentanyl